BioCryst Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview

BioCryst Pharmaceuticals

31/10/2023 18:31

* BioCryst Pharmaceuticals Inc  BCRX.OQ   BCRX.O  is
expected
to show a rise in quarterly revenue when it reports  results 
    * The Durham North Carolina-based  company is expected to
report 
a 13.4% increase in revenue to $85.954 million from $75.83
million a year ago, according to the mean estimate from 10
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for BioCryst
Pharmaceuticals
Inc is for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for BioCryst
Pharmaceuticals Inc is $11.5​, above​ its last closing price
of $5.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.23       -0.23      -0.24     Missed  -5.1
 Mar. 31 2023  -0.30       -0.30      -0.28     Beat    6.3
 Dec. 31 2022  -0.13       -0.17      -0.38     Missed  -124.5
                                                        ​
 Sep. 30 2022  -0.29       -0.29      -0.23     Beat    20.9
 ​​Jun.        -0.36       -0.34      -0.32     Beat    6.8
 30 2022                                                
 Mar. 31 2022  -0.35       -0.37      -0.40     Missed  -9.2​
 Dec. 31 2021  -0.31       -0.30      -0.10     Beat    67.2
 Sep. 30 2021  -0.29       -0.29      -0.33     Missed  -12.1
 This summary was machine generated October 31 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated